Published in final edited form as:

Bioorg Med Chem Lett. 2016 April 15; 26(8): 1869–1872. doi:10.1016/j.bmcl.2016.03.031.

Lead optimization of the VU0486321 series of mGlu₁ PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs

Pedro M. Garcia-Barrantes^a, Hyekyung P. Cho^{a,b}, Anna L. Blobaum^a, Colleen M. Niswender^{a,b}, P. Jeffrey Conn^{a,b}, and Craig W. Lindsley^{a,b,c,*}

^aVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^bDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^cDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

Abstract

This letter describes the further lead optimization of the VU0486321 series of mGlu₁ positive allosteric modulators (PAMs), focused on addressing the recurrent issue of plasma instability of the phthalimide moiety. Here, we evaluated a number of phthalimide bioisosteres, and ultimately identified isoindolinones as the ideal replacement that effectively address plasma instability, while maintaining acceptable mGlu₁ PAM potency, DMPK profile, CNS penetration and mGluR selectivity.

Graphical abstract

Keywords

mGlu₁; Metabotropic glutamate receptor; Positive allosteric modulator (PAM); Schizophrenia; Structure-Activity Relationship (SAR)

Recent genetic data implicating *GRM1* in schizophrenia^{1–3} and studies showing that the adverse affect liabilities of group I metabotropic glutamate receptors (mGluRs) is mediated by mGlu₅ and not mGlu₁,⁴ have rekindled interest in the development of mGlu₁ positive

*To whom correspondence should be addressed: craig.lindsley@vanderbilt.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

allosteric modulators (PAMs).^{3–6} However, early mGlu₁ PAMs lacked the DMPK profiles to serve as robust *in vivo* tool compounds (Figure 1).⁷

In response, our lab has focused efforts on developing novel mGlu₁ PAMs,^{3–6} with an intent to discover the ideal *in vivo* tool compound to then validate the target for multiple neuropsychiatric disorders. Within the phthalimide-based VU0486321 series of mGlu₁ PAMs, most optimization parameters could be effectively addressed (potency, disposition, CNS penetration), except for reoccurring and variable *in vitro* plasma instability due to hydrolysis of the phthalimide moiety.^{3–6,8} In this Letter, we explore phthalimide biosiosteres and other replacements, ultimately identifying isoindolinones as the ideal substitute, and the discovery of VU0487351, a potent, selective, CNS penetrant and stable mGlu₁ PAM tool compound.

The optimization plan targeted expansion of the phthalimide moiety, saturated analogs and sequential deletion of carbonyl moieties to provide isoindolinones and isoindolines (Figure 2) to deliver diverse analogs **6**. The chemistry required is straight forward, as shown in Scheme 1, requiring only three steps from commercial materials to access final compounds **9**, **13** and **16**. Nucleophilic aromatic substitution between **7** and different amines produced intermediates **8**, which were hydrogenated and submitted to amide coupling with 3-methyl-2-furoic acid to give analogs **9**. Functionalized *p*-amino nitroarenes/heteroarenes **10** were condensed with various anhydrides to afford analogs **11**. The nitro group was reduced to the aniline **12** via hydrogenation conditions, and final analogs **6** were afforded by standard amide coupling conditions with a diverse array of heterocyclic carboxylic acids to provide analogs **13**. Alternatively, **7** could be employed to displace benzylic bromides **14**, which upon heating formed the γ -lactams **15**. Then, nitro reduction and acylation would yield the diversely functionalized isoindolinones **16**.⁹

Initially, we evaluated analogs of **3**, and the SAR was intriguing. Expansion of the phthalimide moiety to an isoquinoline dione **17** (Figure 2) afforded a potent mGlu₁ PAM (EC_{50} = 242 nM, pEC_{50} = 6.65 ± 0.09 , 105% Glu Max)¹⁰ with a clean CYP profile, but high intrinsic clearance (13.5 mL/min/kg and 54 mL/min/kg for human and rat, respectively) and was found to be unstable in both rat and human plasma. Further expansion to the 7-membered benzo[*d*]azepine core **18**, led to a significant loss of activity (EC_{50} = 3.5 μ M, pEC_{50} = 5.44 ± 0.08 , 95% Glu Max). Interestingly, a 3,4-dihydroquinolinone congener **19**, was a modest mGlu₁ PAM (EC_{50} = 1.29 μ M, pEC_{50} = 5.88 ± 0.09 , 107% Glu Max) with suprahepatic clearance; however, **19** was stable in human and rat plasma, and suggested lactams may be productive in engendering plasma stability.

Based on these data, we then explored a diverse array of phthalimide replacements **20**, with varying degrees of success (Table 1). Representative examples include **20a** and **20b**, the direct, saturated (both *cis*- and *trans*-isomers) of **3**, which proved to be inactive. The hydrolyzed product of **3**, **20c**, was synthesized and found to be active (EC_{50} = 930 nM, pEC_{50} = 6.03 ± 0.14 , 108% Glu Max); however, **20c** was not CNS penetrant and displayed poor disposition, yet an ‘active’ *in vitro* metabolite. Other benzoates, with diverse functional groups in place of the carboxylic acid were all inactive. Isoindolinone **20e** was active, but the regioisomeric congener **20g** was inactive, and both regioisomeric isoindolines, **20f** and **20h**

were active. **20l**, a regioisomer of **19** was potent ($EC_{50} = 780$ nM, $pEC_{50} = 6.11 \pm 0.12$, 94% Glu Max) as well. Profiling of all the active analogs **20** in our *in vitro* DMPK assays quickly led us to focus on the isoindolinone **17e** ($EC_{50} = 3.72$ μ M, $pEC_{50} = 5.43 \pm 0.19$, 91% Glu Max), as it displayed complete stability in rat and human liver microsomes with low intrinsic clearance. Now, the focus was to improve mGlu₁ PAM potency.

For the next iteration of parallel synthesis, we surveyed functionalized isoindolinone congeners **21**, of the mGlu₁ PAM **3** (Table 2). Gratifyingly, substituents on the isoindolinone phenyl ring increased potency by >10-fold in some cases, providing mGlu₁ PAMs with nanomolar potency.

Evaluation of analogs **21** in our *in vitro* and *in vivo* battery of DMPK assays quickly identified **21a** (VU0487351),^{3–6,11} as an exceptional compound. First, and in contrast to **3–5**, **21a** was hydrolytically stable in rat and human liver microsomes and displayed moderate intrinsic clearance (rat CL_{hep} 54.1 mL/min/kg and human CL_{hep} 8.53 mL/min/kg). Moreover, **21a** had a clean CYP profile (IC_{50} s > 30 μ M against 3A4, 1A2, 2C9 and 2D6), was inactive at mGlu₄ ($EC_{50} > 10$ μ M) and was found to be highly CNS penetrant ($K_p = 1.36$, C_n plasma 193 nM and C_n brain 269 nM). *In vivo*, **21a** displayed favorable rat PK, with a low clearance (CL_p 11.1 mL/min/kg), high distribution volume (V_D 3.36 L/kg) and good half-life ($t_{1/2} = 93$ min, MRT = 302 min). Therefore, the isoindolinone moiety solved the plasma instability issue, as well as affording a favorable *in vitro* and *in vivo* DMPK profile. The only blemish for **21a** was high protein binding (>99% in human and rat plasma, as well as rat brain homogenate binding), which was true for all analogs **21** ($f_u < 0.01$). Therefore, we elected to pursue a matrix library strategy to identify new isoindolinone-based mGlu₁ PAMs that maintained the overall profile of **21a**, while improving fraction unbound.

Analog **22** surveyed SAR for three regions: the central phenyl core, alternative heterocyclic amides and substitutions on the isoindolinone phenyl ring (Table 3). The removal of the hydrogen in the central ring (**22a–c**) led to a similar SAR tendency as the 2-Cl analogs, with **22b** having a comparable potency to **21a**, suggesting that an asymmetric substitution pattern in the central ring is not necessary. Other substitutions, such as 2,3-dichloro (**22d–f**) and 3-fluoro (**22g–i**) caused a dramatic loss in potency. This trend shows how variable and steep the SAR can be in this scaffold, as the 3-fluoro substitution has been an excellent modification to achieve potent and selective mGlu₁ PAM activity in our phthalimide scaffold. As we assessed the replacement of the furan with different heterocycles in the isoindolinone scaffold, a substantial loss in potency was found when using 3-substituted picolinamides, and only the 4-Cl substituted **22h** and **22k** (direct comparators to **21a**) maintained mGlu₁PAM potency of around 1 μ M; while in the thiazole (**22p–r**) congeners the 4-Cl substituted (**22q**) was most potent of the group ($EC_{50} = 950$ nM). However, these attempts to engender improved free fraction in the isoindolinone series failed, and SAR was steep.

In conclusion, the continued optimization of the VU0486321 series of mGlu₁ PAMs led us to pursue alternatives for the phthalimide moiety, plagued with unpredictable plasma instability issues. Here we identified isoindolinones as biosiosteres for the phthalimide group. mGlu₁ PAMs such as **21a**, that retained mGlu₁ PAM potency and mGluR selectivity,

while also affording plasma stability, attractive *in vitro* and *in vivo* PK profiles and high CNS penetration ($K_p = 1.36$). Together, with VU0487351 (**21a**) and VU6004909 (**5**), the field now has mGlu₁ PAMs that can serve as robust *in vivo* tool compounds to further dissect the therapeutic potential of selective mGlu₁ activation.

Acknowledgments

We thank William K. Warren, Jr. and the William K. Warren Foundation who funded the William K. Warren, Jr. Chair in Medicine (to C.W.L.). P.M.G. would like to acknowledge the VISP program for its support. This work was funded by the William K. Warren, Jr. Chair in Medicine and the NIH (U54MH084659).

References

1. Frank RAW, McRae AF, Pocklington AJ, van de Lagemaat LN, Navarro P, Croning MDR, Komiyama NH, Bradley SJ, Challiss RAJ, Armstrong JD, Finn RD, Malloy MP, MacLean AW, Harris SE, Starr JM, Bhaskar SS, Howard EK, Hunt SE, Coffey AJ, Raganath V, Deloukas P, Rogers J, Muir WJ, Deary IJ, Blackwood DH, Visscher PM, Grant SGN. PLoS One. 2011; 6:e19011. [PubMed: 21559497]
2. Ayoub MA, Angelicheva D, Vile D, Chandler D, Morar B, Cavanaugh JA, Visscher PM, Jablensky A, Pflieger KDG, Kalaydjieva L. PLoS One. 2012; 7:e32849. [PubMed: 22448230]
3. Cho HP, Garcia-Barrantes PM, Brogan JT, Hopkins CR, Niswender CM, Rodriguez AL, Venable D, Morrison RD, Bubser M, Daniels JS, Jones CK, Conn PJ, Lindsley CW. ACS Chem Bio. 2014; 9:2334–2346. [PubMed: 25137254]
4. Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW. J Med Chem. 2015; 58:7959–7571. [PubMed: 26426481]
5. Garcia-Barrantes PM, Cho HP, Niswender CM, Blobaum AL, Conn PJ, Lindsley CW. Bioorg Med Chem Lett. 2015; 25:5107–5110. [PubMed: 26476971]
6. Garcia-Barrantes PM, Cho HP, Metts AM, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW. Bioorg Med Chem Lett. 2016; 26:751–756. [PubMed: 26778256]
7. Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J. Bioorg Med Chem Lett. 2009; 19:1666–1669. [PubMed: 19233648]
8. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Daniels JS, Morrison R, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR. J Med Chem. 2011; 54:7639–7647. [PubMed: 21966889]
9. **Representative experimental (21a, VU0487351).** *N*-(3-chloro-4-(4-chloro-1-oxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (**21a**): In a microwave vial, *N*-(4-amino-3-chlorophenyl)-3-methylfuran-2-carboxamide (preparation described in reference 4) (100 mg, 0.399 mmol) and K₂CO₃ (110 mg, 0.798 mmol) were weighted and dissolved in DMF (2 mL). The reaction was stirred for 10 minutes at room temperature followed by addition of 2-(bromomethyl)-3-chlorobenzoate (126 mg, 0.479 mmol). The reaction was heated in a microwave reactor for 15 minutes at 150 °C. The reaction was worked up by addition of water and successive extractions with DCM. The organic phases were combined and filtered through a phase separator. Volatiles were evaporated *in vacuo* and the crude was purified by trituration with cold MeOH. A cream solid was obtained (84.8 mg, 53%). ¹H-NMR (400.1 MHz, CDCl₃) δ (ppm): 8.16 (1H, s), 8.02 (1H, d, *J* = 2.3 Hz), 7.87 (1H, *J* = 7.4 Hz), 7.59 (2H, m), 7.51 (1H, t, *J* = 7.7 Hz), 7.38 (2H, m), 6.42 (1H, s), 4.78 (2H, s), 2.47 (3H, s). ¹³CNMR (100.6 MHz, CDCl₃) δ (ppm): 167.3, 157.2, 142.8, 141.4, 139.8, 138.6, 133.9, 133.1, 131.9, 130.7, 130.1, 129.9, 129.8, 129.2, 122.8, 121.1, 118.7, 116.0, 51.4, 11.2.
- 10.

In vitro molecular pharmacology. Tetracycline-tested fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA), and all other tissue culture reagents and Fluo-4-acetoxymethylester (Fluo-4-AM) were purchased from Life Technologies (Carlsbad, CA). Tetracycline hydrochloride (Sigma), L-glutamic acid (Tocris, Minneapolis, MN), and (S)-3,5-dihydroxy phenylglycine (DHPG) (Abcam, Cambridge, MA). EZ-Link Sulfo-NHS-SS-Biotin and NeutrAvidin agarose beads (Pierce Biotechnology, Rockford, IL). Tetracycline-inducible human mGlu₁ WT-T-RExTM-293 cells (Wu et al, Science 2014) were cultured at 37 °C in Dulbecco's Modified Eagle Medium (DMEM) growth medium containing 10% Tet-tested FBS, 2 mM L-glutamine, 20 mM HEPES, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, antibiotic/antimycotic, 100 µg/mL hygromycin and 5 µg/mL blasticidin in the presence of 5% CO₂. To determine the potency of mGlu₁ PAMs in calcium assays, Ca flux was measured as previously described in *ACS Chem. Bio.* **2014**, *9*, 2334–2346. Briefly, the day before the assay, human mGlu₁ WT-T-RExTM-293 cells were plated in black-walled, clear-bottomed, poly-D-lysine coated 96-well plates at 80,000 cells/100 µL assay medium (DMEM supplemented with 10% dialyzed FBS, 20 mM HEPES, and 1 mM sodium pyruvate) containing 50 ng/mL of tetracycline to induce mGlu₁ expression. The next day, media was removed and the cells were incubated with 50 µL of 1.15 µM Fluo-4 AM dye solution prepared in assay buffer (buffer (Hank's balanced salt solution, 20 mM HEPES, and 2.5 mM probenecid) for 45 min at 37 °C, the dye was removed and replaced with 45 µL of assay buffer. Then, calcium flux was measured using Flexstation II (Molecular Devices, Sunnyvale, CA). Compounds serially diluted at half log concentrations in DMSO were further diluted in assay buffer. The compounds or DMSO vehicle were added to cells and incubated for 2.5 min and an EC₂₀ concentration of glutamate was added and incubated for 1 min. An EC_{max} concentration of glutamate was also added to cells that were incubated with DMSO vehicle to accurately calculate the EC₂₀ calcium response. Data were normalized by subtracting the basal fluorescent peak before EC₂₀ agonist addition from the maximal peak elicited by EC₂₀ agonist and PAMs. Using GraphPad Prism 5.0, the concentration response curves were generated and the potencies of the mGlu₁ PAMs were determined.

11. Gentry PR, Kokubo M, Bridges TM, Byun N, Cho HP, Smith E, Hodder PS, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR. *J Med Chem.* 2014; *57*:7804–7810. [PubMed: 25147929]

Figure 1.
Structures of representative mGlu₁ PAMs **1–5**.

Figure 2.
Chemical optimization plan to replace the phthalimide moiety of **5** with novel analogs **6**.

Figure 3.
Homologated analogs **14–16** of **3** that retained mGlu₁ PAM activity.

Scheme 1.

Reagents and conditions: (a) K_2CO_3 , ACN, 60 °C, 43–89%, (b) H_2 , Pd/C, EtOH, rt, 94–99%; (c) heterocyclic carboxylic acids, HATU, DCM, r.t., 39–98%; (d) aryl anhydrides, AcOH, reflux, 64–94%; (e) K_2CO_3 , DMF, μW , 150 °C, 15 min, 29–92%.

Table 1Structures and activities for analogs **20**.

20			
Cpd	Het	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
20a		>10 [-]	>5
20b		>10 [-]	>5
20c		0.93 [108±7]	6.03±0.14
20d		>10 [-]	>5
20e		3.72 [91±9]	5.43±0.19
20f		1.76 [95±23]	5.75±0.43
20g		>10 [-]	>5

20			
Cpd	Het	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
20h		5.71 [82±8]	5.24±0.14
20i		9.55 [78±2]	5.02±0.09
20j		3.62 [99±9]	5.44±0.14
20k		2.61 [93±4]	5.58±0.07
20l		0.781 [94±4]	6.11±0.12
20m		2.47 [107±5]	5.88±0.09

^a Calcium mobilization mGlu₁ assays, values are average of three (n=3) independent experiments performed in triplicate.

Table 2Structures and activities for analogs **21**.

<p style="text-align: center;">21</p>			
Cpd	R	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
21a	4-Cl	0.211 [88±4]	6.75±0.07
21b	5-Cl	>10 [58±1]	>5
21c	7-Cl	0.484 [108±4]	6.31±0.1
21d	4-Me	1.07 [89±3]	5.96±0.09
21e	4-F	0.878 [82±4]	6.05±0.11
21f	4-Br	0.391 [99±4]	6.41±0.10
21g	4-CF ₃	1.13 [105±5]	5.94±0.09
21h	4-CN	2.09 [107±9]	5.67±0.17
21i	4-OMe	>10 [-]	>5
21j	4-Aza	>10 [-]	>5
21k	7-Aza	>10 [-]	>5
21l	4,7-Aza	>10 [-]	>5
21m	3,3-diMe	6.93 [76±3]	5.15±0.09

^aCalcium mobilization mGlu₁ assays, values are average of three (n=3) independent experiments performed in triplicate.

Table 3Structures and activities for analogs **22**.

22	Cpd	R ¹	R ²	Het	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
	22a	H	H		1.56 [94±12]	5.81±0.31
	22b	H	4-Cl		0.245 [99±3]	6.61±0.11
	22c	H	7-Cl		0.353 [101±3]	6.45±0.11
	22d	2,3-diCl	H		>10 [-]	>5
	22e	2,3-diCl	4-Cl		>10 [-]	>5

22	Cpd	R ¹	R ²	Het	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
	22f	2,3-diCl	7-Cl		6.52 [8] ±6	5.18±0.09
	22g	3-F	H		>10 [-]	>5
	22h	3-F	4-Cl		1.26 [86±6]	5.90±0.15
	22i	3-F	7-Cl		>10 [-]	>5
	22j	2-Cl	H		>10 [-]	>5

22	Cpd	R ¹	R ²	Het	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
	22k	2-Cl	4-Cl		1.36 [97±6]	5.84±0.14
	22l	2-Cl	7-Cl		>10 [78±2]	>5
	22m	2-Cl	H		>10 [-]	>5
	22n	2-Cl	4-Cl		1.27 [93±5]	5.89±0.12
	22o	2-Cl	7-Cl		>10 [51±3]	>5
	22p	2-Cl	H		>10 [33±6]	>5

Cpd	R ¹	R ²	Het	hmGlu ₁ EC ₅₀ (μM) ^a [% Glu Max ±SEM]	mGlu ₁ pEC ₅₀ (±SEM)
22
22q	2-Cl	4-Cl		0.954 [66±4]	6.02±0.12
22r	2-Cl	7-Cl		4.69 [69±2]	5.32±0.73

^aCalcium mobilization mGlu1 assays, values are average of three (n=3) independent experiments performed in triplicate.